Basilea Pharmaceutica Forecast, price target & analysts
Basilea Pharmaceutica Target price 2025 - Analyst rating & recommendation
Basilea Pharmaceutica Classifications & Recommendation:
Basilea Pharmaceutica Price Target
| Target Price | CHF74.90 |
| Price | CHF44.75 |
| Potential |
67.37%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Basilea Pharmaceutica 2026 .
The average Basilea Pharmaceutica target price is CHF74.90.
This is
67.37%
register free of charge
CHF100.00
123.46%
register free of charge
CHF60.70
35.64%
register free of charge
|
|
| A rating was issued by 3 analysts: 2 Analysts recommend Basilea Pharmaceutica to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Basilea Pharmaceutica stock has an average upside potential 2026 of
67.37%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 208.54 | 216.29 |
| 32.30% | 3.72% | |
| EBITDA Margin | 30.17% | 24.16% |
| 128.84% | 19.91% | |
| Net Margin | 37.21% | 12.30% |
| 461.23% | 66.94% |
4 Analysts have issued a sales forecast Basilea Pharmaceutica 2025 . The average Basilea Pharmaceutica sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Basilea Pharmaceutica EBITDA forecast 2025. The average Basilea Pharmaceutica EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Basilea Pharmaceutica 2025 . The average Basilea Pharmaceutica net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 5.60 | 2.20 |
| 543.68% | 60.71% | |
| P/E | 20.34 | |
| EV/Sales | 2.40 |
1 Analysts have issued a Basilea Pharmaceutica forecast for earnings per share. The average Basilea Pharmaceutica EPS is
This results in the following potential growth metrics and future valuations:
Basilea Pharmaceutica...
Current Basilea Pharmaceutica Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Mar 23 2025 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Dec 22 2024 |
| BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Dec 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Mar 25 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Mar 23 2025 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Dec 22 2024 |
|
Locked
BRYAN GARNIER:
Locked
➜
Locked
|
Dec 15 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
